REACT-SCOT Pharmacoepidemiology (REACT-SCOT-PHARM)

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/38213
• EU PAS number:
  EUPAS35558
• Study ID:
  38213
• Official title and acronym:
  REACT-SCOT Pharmacoepidemiology (REACT-SCOT-PHARM)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  Observational analysis of the association of COVID-19 with drug exposures: A case control study in the population of Scotland
• Study status:
  Ongoing

Research institution and networks

Institutions

University of Edinburgh

United Kingdom

Public Health Scotland Glasgow, Scotland

Study timelines

Date when funding contract was signed

Planned: 01/05/2020

Actual: 01/05/2020

Study start date

Planned: 01/03/2020

Actual: 01/03/2020

Data analysis start date

Planned: 01/05/2020

Actual: 01/05/2020

Date of interim report, if expected

Planned: 05/06/2020

Date of final study report

Planned: 12/06/2020

Sources of funding

Other

More details on funding

Public Health Scotland

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable